Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > LATEST
LATEST
-
BUSINESS UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
-
REGULATORY MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
March 3, 2026
-
REGULATORY MHLW Details New Operational Rules for Conditional Approvals from May
March 3, 2026
-
ACADEMIA Japan Begins Investigator-Led PII of Padcev in Small Bowel Adenocarcinoma
March 3, 2026
-
BUSINESS Itochu Snaps Up CoreMed to Bolster Japan Entry Support
March 3, 2026
-
BUSINESS Ono to Transfer Opalmon, Prostandin to Daito by November
March 3, 2026
-
BUSINESS Epadel Launched in Vietnam: Mochida/Meiji
March 3, 2026
-
REGULATORY MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
-
BUSINESS Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
-
BUSINESS FDA Places Clinical Hold on MPS Gene Therapies: Regenxbio/Nippon Shinyaku
January 30, 2026
-
BUSINESS Astellas Positions Izervay as Key Entry Drug in Ophthalmology Push
January 30, 2026
-
BUSINESS Chugai Logs Solid 2025 Results on Overseas Growth, Profit Margin Nears 50%
January 30, 2026
-
BUSINESS Zynlonta Hits Primary Endpoint in Japanese PI/II Study: Tanabe
January 30, 2026
-
BUSINESS Towa Chief Urges Better Use of Innovators’ LLP Manufacturing Assets, Calls Otsuka Deal a “First Step”
January 30, 2026
-
REGULATORY Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
-
BUSINESS Takeda Raises Full-Year Forecast on Weaker Yen Assumptions
January 30, 2026
-
REGULATORY MHLW to Ease Uniform Driving Restrictions on Oral Antiepileptics
January 29, 2026
-
REGULATORY MHLW Eyes Distribution Rules in Revamped Supply Support Premium: Chuikyo
January 29, 2026
-
BUSINESS Chugai Files Tecentriq in Adjuvant Use for MRD-Positive Bladder Cancer
January 29, 2026
-
REGULATORY Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks
January 29, 2026
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…